Alkeus Pharmaceuticals raises $800.0M (United States, Aug 2026)

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M - BioPharma Dive

Alkeus Pharmaceuticals is a biotechnology startup focused on developing a treatment for Stargardt disease, a genetic condition that leads to progressive vision loss. The company is notable for its innovative drug, gildeuretinol, which has shown promise in clinical trials and is now being acquired by Tarsus Pharmaceuticals for up to $800 million.

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M  BioPharma Dive